Middle East and Africa Cancer Supportive Care Products Market, By Drug Type (Granulocyte Colony Stimulating Factor (GCSFS), Erythropoietin Stimulating Agents (ESA’S), Opioid Analgesics, Monoclonal Antibodies, Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Bisphosphonates, Anti-Emetics, Antihistamines and Others), Type (Branded and Generics), Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukaemia, Melanoma, Ovarian Cancer and Other Cancers), End User (Hospitals, Clinics, Hospitals & Academic Institutions and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Compounding Pharmacies), Country (Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Middle East and Africa Cancer Supportive Care Products Market
Cancer supportive care products market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 3.0% in the forecast period of 2021 to 2028 and is expected to reach USD 475.40 million by 2028 from USD 378.32 million in 2020.
Increasing demand of cancer supportive care products, rising government initiatives are the major drivers which boost the demand of the market in the forecast period. Cancer supportive care products market has gained a wide attraction during the last years due to growing government initiative. Moreover, increasing incidence and prevalence of cancer disease as well as rising product launches has also given boom to market growth.
Major factors driving the growth of the cancer supportive care products market are increase in government initiation to control the expansion of cancer and the factor which hampers the growth of the cancer supportive care products market are side effects associated with cancer supportive care products. The partnerships and acquisitions by major market players act as opportunity for the growth of global cancer supportive care products market.
The cancer supportive care products market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Cancer Supportive Care Products Market Scope and Market Size
Middle East and Africa cancer supportive care products market is categorized into five notable segments which are based on drug type, type, cancer type, end user, and distribution channel.
- On the basis of drug type, the cancer supportive care products market is segmented into granulocyte colony stimulating factor (GCSFs), erythropoietin stimulating agents (ESA’s), opioid analgesics, monoclonal antibodies, nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, anti-emetics, and antihistamines and others. In 2021, granulocyte colony stimulating factor (GCSFs) segment is dominating the cancer supportive care products market as it stimulates the bone marrow and generates stem cells as well as granulocytes to discharge it in bloodstream. Moreover, granulocyte colony stimulating factor (GCSFS) is primarily used to treat and cure the neutropenia caused owing to cancer chemotherapy treatment.
- On the basis of type, the cancer supportive care products market is segmented into branded and generics. In 2021, generics segment is dominating the cancer supportive care products market since it is cost effective, easily accessible and primarily recommended by doctors for cancer supportive care products diseases.
- On the basis of cancer type, the cancer supportive care products market is segmented into lung cancer, breast cancer, prostate cancer, liver cancer, bladder cancer, leukaemia, melanoma, ovarian cancer and other cancers. In 2021, the lung cancer segment is dominating the cancer supportive care products market due to growing smoking habits among populace in developed as well as developing country.
- On the basis of end user, the cancer supportive care products market is segmented into hospitals, clinics, hospitals & academic institutions and others. In 2021, hospitals segment is dominating the cancer supportive care products market as it provides patients with the best healthcare services. Moreover, hospitals are the primary healthcare service provider for patients suffering from cancer.
- On the basis of distribution channel, the cancer supportive care products market is segmented into hospital pharmacies, retail pharmacies and compounding pharmacies. In 2021, hospital pharmacies segment is dominating the cancer supportive care products market as most of the medicines are procured through hospital pharmacies. The increasing adoption of prescription based medicines, also acts as driver for the cancer supportive care products market growth.
Cancer Supportive Care Products Market Country Level Analysis
The cancer supportive care products market is analysed and market size information is provided by drug type, type, cancer type, end user and distribution channel.
The countries covered in the cancer supportive care products market report are Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East and Africa.
South Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028, in Middle East and Africa countries. The government organization and healthcare bodies are under taking various programs in this region, consequently it anticipated to propel the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Partnership and Distribution Agreement with Local Players, is Creating New Opportunities for Players in the Cancer supportive Care Products Market
Cancer supportive care products market also provides you with detailed market analysis for every country growth in cancer supportive care products product’s industry. Additionally, it provides detail information regarding growing partnership and distribution agreement with local players. The data is available for historic period 2011 to 2019.
Competitive Landscape and Cancer Supportive Care Products Market Share Analysis
Cancer supportive care products market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to cancer supportive care products market.
The major players covered in the report are Amgen Inc., Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), Pfizer Inc., APR, Novartis AG, F. Hoffmann-La Roche Ltd., Acacia Pharma Group Plc., Baxter, Bayer AG, Helsinn Healthcare SA., Heron Therapeutics, Inc., Kyowa Kirin Co., Ltd., Acrotech Biopharma, Spectrum Pharmaceuticals, Inc., Oxford Pharmascience Ltd, Merck Sharp & Dohme Corp. (A Subsidiary of Merck & Co., Inc.), Teva (A Subsidiary of Teva Pharmaceutical Industries Ltd.), Tersera Therapeutics Llc., Mylan N.V., Sun Pharmaceutical Industries Ltd., among other Middle East and Africa players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product approval and agreement are also initiated by the companies’ worldwide which are also accelerating the cancer supportive care products market.
- In January 2020 Novartis AG declared the acquisition with the Medicines Company. This acquisition has provided novel opportunity to the company to escalate its geographical presence across the world. As well as it has helped in upgrading the product portfolio of the company.
Collaboration, joint ventures and other strategies by the market player is enhancing the company presence in the Cancer supportive care products market which also provides the benefit for organisation.
SKU-